Clinical significance of circulating galectins as colorectal cancer markers

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1217-1226

  Makoto, Watanabe ^a,b   Ichiro, Takemasa ^a   Naoki, Kaneko ^a,b   Yuhki, Yokoyama ^a   Matsuo, Ei Ichi ^a,b   Susumu, Iwasa ^b   Masaki, Mori ^a   Nariaki, Matsuura ^a   Morito, Monden ^a   Osamu, Nishimura ^a  

^a OSAKA UNIVERSITY   (Japan)

^b SHIMADZU CORPORATION   (Japan)

Author keywords

Biomarker; Colorectal cancer; ELISA; Galectin; Plasma

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GALECTIN; GALECTIN 1; GALECTIN 2; GALECTIN 3; GALECTIN 4; GALECTIN 7; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; GALECTINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953043430     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1198     Document Type: Article

References (35)

1. Locker GY, Hamilton S, Harris JM, Jessup JM, Kemeny, N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
2. Gutman S and Kessler LG: The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 6: 565-571, 2006. (Pubitemid 43980545)
3. Grossmann I, de Bock GH, Meershoek-Klein Kranenbarg WM, van de Velde CJ and Wiggers T: Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol 33: 183-187, 2007. (Pubitemid 46336557)
4. Kuramitsu Y and Nakamura K: Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 6: 5650-5661, 2006. (Pubitemid 44683228)
5. Matsuo E, Watanabe M, Kuyama H and Nishimura O: A new strategy for protein biomarker discovery utilizing 2-nitrobenzenesulfenyl (NBS) reagent and its applications to clinical samples. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2607-2614, 2009.
6. Watanabe M, Takemasa I, Kawaguchi N, Miyake M, Nishimura N, Matsubara T, Matsuo E, Sekimoto M, Nagai K, Matsuura N, Monden M and Nishimura O: An application of the 2-nitrobenzenesulfenyl method to proteomic profiling of human colorectal carcinoma: a novel approach for biomarker discovery. Proteomics Clin Appl 2: 925-935, 2008. (Pubitemid 351943773)
7. Kasai K and Hirabayashi J: Galectins: a family of animal lectins that decipher glycocodes. J Biochem 119: 1-8, 1996. (Pubitemid 26048050)
8. Yang RY and Liu FT: Galectins in cell growth and apoptosis. Cell Mol Life Sci 60: 267-276, 2003.
9. Dagher SF, Wang JL and Patterson RJ: Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 92: 1213-1217, 1995.
10. Wang JL, Gray RM, Haudek KC and Patterson RJ: Nucleocytoplasmic lectins. Biochim Biophys Acta 1673: 75-93, 2004. (Pubitemid 38844796)
11. Vyakarnam A, Dagher SF, Wang JL and Patterson RJ: Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 17: 4730-4737, 1997. (Pubitemid 27318148)
12. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
13. Danguy A, Camby I and Kiss R: Galectins and cancer. Biochim Biophys Acta 1572: 285-293, 2002. (Pubitemid 35246351)
14. Nagy N, Legendre H, Engels O, Andre S, Kaltner H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ, Salmon I and Kiss R: Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 97: 1849-1858, 2003.
15. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, Shindo K and Yasutomi M: Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15: 143-148, 1999.
16. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R and Camby I: Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 103: 370-379, 2003. (Pubitemid 36076430)
17. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain GC, Vertongen F, Toubeau G, Decaestecker C and Kiss R: The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncology 44: 86-93, 2008. (Pubitemid 350251284)
18. Saussez S and Kiss R: Galectin-7 Cell Mol Life Sci 63: 686-697, 2006.
19. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R and Gabius HJ: Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50: 392-401, 2002. (Pubitemid 34161058)
20. Sobin LH and Wittekind Ch (eds): TNM Classification of malignant tumors. 5th edition. John Wiley & Sons, Inc., New York, 1997.
21. Youden WJ: Index for rating diagnostic tests. Cancer 3: 32-35, 1950.
22. Yamashita K and Watanabe M: Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100: 195-199, 2009.
23. Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, De Paoli M, Plebani M and Tulassay Z: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8: 194, 2008.
24. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ and Haglund C: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101: 545-548, 2002.
25. Rabinovich GA, Ariel A, Hershkoviz R, Hirabayashi J, Kasai KI and Lider O: Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97: 100-106, 1999. (Pubitemid 29217266)
26. Chung CD, Patel VP, Moran M, Lewis LA and Miceli MC: Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165: 3722-3729, 2000. (Pubitemid 32057278)
27. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL and Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251, 2004. (Pubitemid 38402116)
28. He J and Baum LG: Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 279: 4705-4712, 2004. (Pubitemid 38199064)
29. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC and Chung LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761, 1991.
30. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y and Nakamura T Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57: 3305-3313, 1997. (Pubitemid 27351751)
31. Janvier R, Sourla A, Koutsilieris M and Doillon CJ : Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res 17: 1551-1557, 1997. (Pubitemid 27257644)
32. Anderson IC, Mari SE, Broderick RJ, Mari BP and Shipp MA: The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res 60: 269-272, 2000. (Pubitemid 30070749)
33. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG and Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851, 2004. (Pubitemid 38174665)
34. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Kloppel G, Kalthoff H, Folsch UR and Schafer H: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64: 1331-1337, 2004. (Pubitemid 38235601)
35. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M and Park M: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527, 2008. (Pubitemid 351655218)